AW
GENB

Avion Wealth’s Generate Biomedicines GENB Stock Holding History

Avion Wealth’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Buy
200
+100
+100% +$1.36K ﹤0.01% 1014
2026
Q1 		$1K Buy
+100
New +$1.22K ﹤0.01% 1193

Other funds holding GENB

AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Avion Wealth's GENB Position: Q2 2026 in Review

Avion Wealth increased its Generate Biomedicines (GENB) stake by 100% in Q2 2026, buying an estimated $1.36K and bringing the position to 200 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

Avion Wealth first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Avion Wealth held 200 shares of Generate Biomedicines worth $3K as of Q2 2026.
  • Avion Wealth bought 100 Generate Biomedicines shares in Q2 2026, an estimated $1.36K.
  • Generate Biomedicines made up ﹤0.01% of Avion Wealth's portfolio in Q2 2026, its #1014 holding.
  • Avion Wealth first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.